Insider Buying: NeoGenomics, Inc. (NASDAQ:NEO) CEO Purchases $148,932.00 in Stock

NeoGenomics, Inc. (NASDAQ:NEO) CEO Anthony P. Zook bought 18,900 shares of NeoGenomics stock in a transaction that occurred on Tuesday, May 6th. The stock was bought at an average cost of $7.88 per share, with a total value of $148,932.00. Following the completion of the purchase, the chief executive officer now owns 18,900 shares in the company, valued at approximately $148,932. This trade represents a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which is accessible through this link.

NeoGenomics Stock Down 1.0 %

NEO stock opened at $8.05 on Friday. The business has a 50-day simple moving average of $9.21 and a 200 day simple moving average of $13.08. The company has a market cap of $1.04 billion, a PE ratio of -12.98 and a beta of 1.60. The company has a quick ratio of 1.91, a current ratio of 1.98 and a debt-to-equity ratio of 0.38. NeoGenomics, Inc. has a 52 week low of $6.08 and a 52 week high of $19.12.

NeoGenomics (NASDAQ:NEO) last released its quarterly earnings data on Tuesday, April 29th. The medical research company reported ($0.08) earnings per share for the quarter, missing the consensus estimate of ($0.02) by ($0.06). The business had revenue of $168.04 million during the quarter, compared to analyst estimates of $171.38 million. NeoGenomics had a negative net margin of 11.92% and a negative return on equity of 2.10%. The business’s quarterly revenue was up 7.6% compared to the same quarter last year. During the same period last year, the business earned ($0.02) earnings per share. Sell-side analysts anticipate that NeoGenomics, Inc. will post -0.2 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the company. Bank of America dropped their price objective on NeoGenomics from $19.00 to $16.00 and set a “neutral” rating on the stock in a research note on Wednesday, February 19th. Piper Sandler set a $12.00 target price on shares of NeoGenomics and gave the company an “overweight” rating in a report on Tuesday. StockNews.com lowered NeoGenomics from a “hold” rating to a “sell” rating in a research note on Monday, May 5th. Leerink Partners cut NeoGenomics from an “outperform” rating to a “market perform” rating and dropped their price target for the company from $25.00 to $9.00 in a research note on Wednesday, April 30th. Finally, Needham & Company LLC decreased their price objective on shares of NeoGenomics from $18.00 to $8.50 and set a “buy” rating on the stock in a report on Tuesday, April 29th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, NeoGenomics has an average rating of “Hold” and a consensus target price of $13.83.

Institutional Trading of NeoGenomics

Hedge funds have recently added to or reduced their stakes in the stock. SBI Securities Co. Ltd. bought a new position in shares of NeoGenomics in the 4th quarter valued at $26,000. Versant Capital Management Inc raised its position in NeoGenomics by 174.9% in the fourth quarter. Versant Capital Management Inc now owns 1,795 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 1,142 shares during the last quarter. CWM LLC boosted its stake in shares of NeoGenomics by 42.6% during the first quarter. CWM LLC now owns 6,299 shares of the medical research company’s stock valued at $60,000 after purchasing an additional 1,883 shares in the last quarter. Sterling Capital Management LLC grew its holdings in shares of NeoGenomics by 788.7% during the fourth quarter. Sterling Capital Management LLC now owns 3,706 shares of the medical research company’s stock worth $61,000 after purchasing an additional 3,289 shares during the last quarter. Finally, Smartleaf Asset Management LLC increased its stake in shares of NeoGenomics by 203.6% in the fourth quarter. Smartleaf Asset Management LLC now owns 4,156 shares of the medical research company’s stock valued at $70,000 after buying an additional 2,787 shares during the period. Institutional investors and hedge funds own 98.50% of the company’s stock.

About NeoGenomics

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.